This trial is studying whether adding inotuzumab ozogamicin to standard chemotherapy for high-risk B-cell acute lymphoblastic leukemia (B-ALL) improves outcomes.
1 Primary · 4 Secondary · Reporting Duration: From study entry to first event (induction failure, Induction death, end of induction (EOI) minimal residual disease (MRD) >= 5%, EOC MRD >= 0.01%, relapse, second malignancy, remission death) or date of last contact, assessed up to 5 years
4772 Total Participants · 5 Treatment Groups
Primary Treatment: Arm I (HR-FAV B-ALL) · No Placebo Group · Phase 3
Age 1 - 24 · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: